The LYCRA Company Launches LYCRA EnviroFit™ Fiber at INDEX™ 23
13.4.2023 12:00:00 EEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the personal care and apparel industries, is exhibiting its newest fiber innovations for hygiene and personal care products at INDEX™ 23, the world’s leading nonwovens exhibition, which takes place at Palexpo in Geneva, Switzerland, April 18 – 21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230413005005/en/
The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber for personal care products at INDEX™ 23, April 18 – 21. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping to conserve resources without compromising product performance. (Photo: Business Wire)
At the trade show, The LYCRA Company is commercially launching LYCRA EnviroFit™ fiber, one of the many fibers that the company has developed as part of its Planet Agenda sustainability platform. With its unique chemistry, LYCRA EnviroFit™ fiber utilizes thinner yarns, reducing the amount of fiber per article and helping conserve resources without compromising product performance.
“We are thrilled to introduce LYCRA EnviroFit™ fiber, which reduces fiber weight while maintaining the overall quality and performance that personal care products require,” said Scott Blackadar, president, personal care at The LYCRA Company. “Having less mass means fewer resources and less energy are consumed during diaper production. This fiber will appeal to manufacturers who want to significantly reduce their product’s environmental impact and help improve its carbon footprint.”
In addition to continuously improving its range of fibers for personal care products, The LYCRA Company also focuses on providing total solutions for the challenges its customers face. The company is offering two unique delivery technologies aimed at improving the spandex unwinding process and improving diaper line productivity that will also be promoted at the show.
Introducing Trio Loop Yarn Control
The LYCRA Company is showcasing the Trio Loop Technology at INDEX™ 23, the latest yarn control system from BTSR International S.p.A. Trio Loop Technology, in combination with MATRIXCUBE tension controlled plug-and-play unwinding systems, improves yarn tension control and adds more troubleshooting options to further improve diaper line productivity.
Distributing Knotter Type 093E
The LYCRA Company is also the exclusive global distributor of the new and improved Knotter Type 093E for diaper production. This breakthrough innovation by Mesdan S.p.A. offers manufacturers greater efficiency and reliability by eliminating manual knot tying and reducing machine stops.
“By offering these delivery technologies, we are demonstrating that we are a trusted and highly valued solution provider in the industry,” said Werner Hopstaken, global director, personal care at The LYCRA Company. “We are excited to offer our personal care customers these innovative products by BTSR and Mesdan and encourage them to contact us to learn more.”
Visit The LYCRA Company representatives at INDEX™ 23 stand number 2151 or visit this website to discover more benefits of these innovations.
About INDEX™ 23
INDEX™ 23 is the largest global trade show for the nonwovens market. Held every three years, it attracts thousands of visitors from over 100 countries in every region. In addition to its exhibit space, INDEX™ hosts free industry workshops, seminars, tutorials, and presentations during the show. For more information, visit indexnonwovens.com.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, marketing support, and LYCRA ONE™ marketplace. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit lycra.com.
LYCRA EnviroFit™ is a trademark of The LYCRA Company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005005/en/
Contact information
Werner Hopstaken
werner.hopstaken@lycra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom